Abstract |
Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II dose escalation trial with the NK-cell activating bispecific monoclonal antibody HRS-3/A9 which is directed against the Fcgamma-receptor III (CD16 antigen) and the Hodgkin's associated CD30 antigen, respectively. HRS-3/A9 was given four times every 3-4 days starting with 1 mg/m2. The treatment was well tolerated and the maximum tolerated dose was not reached at 64 mg/m2, the highest dose given due to limited amounts of HRS-3/A9 available. Mild to moderate side effects occured in six patients and consisted of fever, pain in involved lymph nodes, and a maculopapulous rash. Median counts of NK-cells and of all lymphocyte subsets were considerably decreased in the patients before therapy and showed no consistent changes under therapy. Eight patients developed human anti-mouse immunoglobulin antibodies, and five patients showed an allergic reaction after attempted retreatment. One complete and one partial remission (lasting 6 and 3 months, respectively), three minor responses (lasting 1 to 15 months), two disease stabilizations (for 2 and 17 months, respectively), and one mixed response were achieved. There was no clearcut dose-side effect or dose-response correlation. Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the murine bispecific antibodies.
|
Authors | F Hartmann, C Renner, W Jung, M Pfreundschuh |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 31
Issue 3-4
Pg. 385-92
(Oct 1998)
ISSN: 1042-8194 [Print] United States |
PMID | 9869203
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Bispecific
- Ki-1 Antigen
- Receptors, IgG
|
Topics |
- Adult
- Animals
- Antibodies, Bispecific
(administration & dosage, adverse effects, immunology)
- Dose-Response Relationship, Drug
- Female
- Hodgkin Disease
(drug therapy, immunology)
- Humans
- Immunotherapy
- Ki-1 Antigen
(immunology)
- Killer Cells, Natural
(immunology)
- Lymphocyte Activation
- Male
- Mice
- Middle Aged
- Receptors, IgG
(immunology)
|